Winter respiratory season, why October is the real deadline

The winter respiratory and immunity season is the largest seasonal block in the Indian supplement calendar, and it is also the longest, demand builds from late October, runs strongly through November to January, and tapers through February.

A four-month selling season sounds forgiving. It is not, because the entry deadline is in early October and the season’s own length is what makes brands complacent about it.

And there is a second reason October matters more here than in any other season, which has nothing to do with logistics: this is the category where the pressure to print claims is at its highest, and the claims review is the step that gets compressed when the schedule slips.

This is orientation, not legal, regulatory or medical advice. Claims rules and market conditions change. Verify the current position with a competent regulatory consultant. For any illness, see a doctor.

Why the deadline is October and not November

Work backwards from the demand curve, which has two distinct phases.

The early phase, late October to mid-November, is where the customers who buy deliberately arrive, the ones who buy before they need it, repeat buyers from last year, and the gifting and family-stocking purchases around the festive period.

The late phase, December to January, is where volume is highest but the market is crowded, advertising is expensive, and you are competing on price with everyone who stocked properly.

Capturing only the late phase is a worse business, and it is what arriving in December gets you.

So the target is stock live by mid-October, which means:

Dispatch by late September or the first days of October.

Manufacturing complete by mid-to-late September.

Slot booked and raw material secured by August, and August matters because several winter-relevant botanicals are priced and allocated well ahead of the season.

Artwork, claims review and plates by July or early August.

And formulation locked by June or July, with development and stability work earlier still if the product is new.

Which puts the real decision in the middle of the year, for a season that starts in late October.

The raw material point, which is specific to this season

This category concentrates demand on a narrow set of ingredients, all at once.

Which produces the predictable annual pattern: prices for the season’s core botanicals rise through August and September, availability of good-quality standardised material tightens, and the brands that booked in July pay less than the brands that booked in September for the same specification.

And the worse consequence is substitution pressure. When good material is tight and a brand needs stock, the temptation is to accept a lower standardisation grade at the original price. We have written about why that is the most invisible change in this business, and this season is when it happens most.

The practical instruction: book the material, not just the slot. A manufacturing slot without secured raw material at a specified standardisation is half a booking.

The claims problem, which is the real story of this season

And this needs to be the longest section, because it is where the damage happens.

This is the category where brands most want to write “boosts immunity”, and it is not an authorised claim, it is not a meaningful statement, and it is the most heavily enforced phrase in the Indian supplement market.

The immune system is not a quantity that increases. A genuinely elevated immune response is an autoimmune problem, not a benefit. So the phrase describes nothing even before you reach the regulatory question.

The pressure is seasonal and intense: the competition is using it, the customer searches for it, and the brand’s marketing team can see the traffic going to listings that say it.

What goes wrong when the schedule slips is specific. The claims review is the step with no physical output, no plate, no carton, no batch, so it is the step that gets shortened. And a listing published in a hurry in November with the phrase on it is pulled in November, which is the worst possible month for it to happen.

What you can say instead, and it is not nothing. Where your product delivers a meaningful amount of vitamin C, vitamin D or zinc, authorised nutrient-function wording exists for those nutrients, specific, checkable, and available to you. Check the current authorised text rather than paraphrasing it.

For botanicals there are no authorised health claims, so write the specification: the botanical name, the part used, the extract ratio, the marker compound, the percentage, the test method, and the batch certificates.

And this is the season when that approach differentiates most, because every competitor is writing the same prohibited sentence.

The second claims trap: dengue and platelets

It belongs in this section even though its season is slightly different, because the stock decisions overlap.

Papaya leaf products and platelet claims are a recurring enforcement target, and more importantly a genuine safety problem.

The harm is not regulatory. It is a family treating dengue at home with a supplement while platelets fall, instead of going to hospital.

We decline these claims and we think any manufacturer should. If a client wants this printed, the honest answer is no.

The gifting overlap

A practical point that affects pack decisions.

The festive period sits inside the early phase of this season, which means a share of winter immunity demand arrives as gifting and family stocking rather than individual purchase.

That changes what sells: larger packs, multi-packs, and presentable packaging do better in late October and November than they do in January.

And it means the pack decision has to be made at the same time as the formulation decision, because a gift-suitable carton needs its own plates and its own lead time. We have written separately about festive gifting and premium packs.

Planning the exit

The season’s length makes this easier than the January categories, and it still needs a number.

Decide what stock you want remaining on 1 February. Winter stock that does not sell by mid-February sits until the following October, ten months, against a shelf life that is already partly consumed.

And watch the shelf-life arithmetic: a product manufactured in September with 24 months, held unsold through February, carried for ten months and sold the following winter, reaches the customer with roughly six to eight months remaining. That is a product a careful buyer will decline, and a retailer will certainly decline.

So the second-season plan for leftover winter stock is usually worse than discounting it in February.

The calendar

June to July, formulation and specification locked. Development and stability for new products.

July to early August, artwork, unrushed claims review, plates.

August, manufacturing slot booked and raw material secured at a specified standardisation.

Mid-to-late September, manufacturing complete, tested and released.

Late September to early October, dispatch, inbound, listings live.

Mid-October, stock live, content published.

Late October to January, sell, with the early phase being the valuable one.

February, clear, against the remainder number you set in advance.

The short version

1. The season runs late October to February, four months, and still unforgiving
2. The entry deadline is early October, and the length breeds complacency
3. Two phases: deliberate buyers early, crowded volume late
4. Arriving in December captures only the expensive phase
5. So target stock live by mid-October
6. Dispatch by late September, manufacturing complete by mid-September
7. Slot booked and material secured by August
8. Artwork, claims review and plates by July or early August
9. Formulation locked by June or July
10. Which puts the real decision in mid-year
11. This category concentrates demand on a narrow ingredient set at once
12. Prices rise through August and September; good material tightens
13. Brands booking in July pay less than brands booking in September
14. The worse consequence is substitution pressure on standardisation
15. Book the material, not just the slot
16. A slot without secured material at a specified grade is half a booking
17. This is the category where claims pressure is highest
18. “Boosts immunity” is unauthorised, meaningless, and heavily enforced
19. The immune system is not a quantity that increases
20. A genuinely elevated immune response is an autoimmune problem
21. The claims review has no physical output, so it gets compressed
22. A rushed November listing is pulled in November
23. Authorised nutrient-function wording exists for vitamin C, D and zinc
24. Check the current text rather than paraphrasing it
25. For botanicals, write the specification instead
26. Which differentiates most in the season when everyone writes the same sentence
27. Dengue and platelet claims: enforced, and a genuine safety problem
28. The harm is a family at home while platelets fall
29. The festive period sits inside the early phase
30. So larger packs and presentable packaging sell better in November than January
31. Gift cartons need their own plates and lead time
32. Set your 1 February remainder number in advance
33. Unsold winter stock waits ten months for the next season
34. A September product sold the next winter arrives with six to eight months left
35. Which a careful buyer and any retailer will decline
36. So February discounting usually beats holding for next season

Related guides: the seasonal demand calendar, supplement label compliance in India, how to choose a contract manufacturer. Related reading: when to order stock for each season, सर्दी के मौसम के लिए स्टॉक कब मंगाएँ, the January weight-loss peak, and the claims that get your listing pulled.